Neurological and Neurodegenerative Alterations in a Transgenic Mouse Model Expressing Human α-Synuclein under Oligodendrocyte Promoter: Implications for Multiple System Atrophy

Multiple system atrophy (MSA) is a progressive, neurodegenerative disease characterized by parkinsonism, ataxia, autonomic dysfunction, and accumulation of α-synuclein (α-syn) in oligodendrocytes. To better understand the mechanisms of neurodegeneration and the role of α-syn accumulation in oligodendrocytes in the pathogenesis of MSA, we generated transgenic mouse lines expressing human (h) α-syn under the control of the murine myelin basic protein promoter. Transgenic mice expressing high levels of hα-syn displayed severe neurological alterations and died prematurely at 6 months of age. Furthermore, mice developed progressive accumulation of hα-syn-immunoreactive inclusions in oligodendrocytes along the axonal tracts in the brainstem, basal ganglia, cerebellum, corpus callosum, and neocortex. The inclusions also reacted with antibodies against phospho-serine (129) hα-syn and ubiquitin, and hα-syn was found in the detergent-insoluble fraction. In high-expresser lines, the white matter tracts displayed intense astrogliosis, myelin pallor, and decreased neurofilament immunostaining. Accumulation of hα-syn in oligodendrocytes also leads to prominent neurodegenerative changes in the neocortex with decreased dendritic density and to loss of dopaminergic fibers in the basal ganglia. The oligodendrocytic inclusions were composed of fibrils and accompanied by mitochondrial alterations and disruption of the myelin lamina in the axons. Together, these studies support the contention that accumulation of α-syn in oligodendrocytes promotes neurodegeneration and recapitulates several of the key functional and neuropathological features of MSA.

[1]  A. Makrigiannakis,et al.  Endometrial Pinopodes and Uterine Receptivity , 2003, Annals of the New York Academy of Sciences.

[2]  K. Wakabayashi,et al.  An autopsy case of early (“minimal change”) olivopontocerebellar atrophy (multiple system atrophy-cerebellar) , 2005, Acta Neuropathologica.

[3]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[4]  Nancy A. Jenkins,et al.  Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[6]  D. Oppenheimer,et al.  Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. , 1969, Journal of neurology, neurosurgery, and psychiatry.

[7]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[8]  P. Lantos,et al.  Cellular pathology of multiple system atrophy: a review. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[9]  Werner Poewe,et al.  Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. , 2005, The American journal of pathology.

[10]  M. Beal.  Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[11]  E. Masliah,et al.  Neurofibrillary Pathology in Transgenic Mice Overexpressing V717F β‐Amyloid Precursor Protein , 2001, Journal of neuropathology and experimental neurology.

[12]  David F. Clayton,et al.  The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.

[13]  J. Trojanowski,et al.  Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model , 2001 .

[14]  L. Mucke,et al.  Central nervous system damage produced by expression of the HIV-1 coat protein gpl20 in transgenic mice , 1994, Nature.

[15]  Carlo Colosimo,et al.  Multiple system atrophy , 2004, The Lancet Neurology.

[16]  W. Honer,et al.  Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. , 1998, The American journal of pathology.

[17]  F. Doricchi,et al.  Attentional functions in multiple system atrophy and Parkinson's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[18]  E. Masliah,et al.  Reduced Neuritic Outgrowth and Cell Adhesion in Neuronal Cells Transfected with Human α-Synuclein , 2001, Molecular and Cellular Neuroscience.

[19]  P. Gonzalez-Cabrera,et al.  Mice expressing the α1B‐adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation , 2002, Journal of neurochemistry.

[20]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[21]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[22]  Takeshi Iwatsubo,et al.  Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia , 1998, Cell Death and Differentiation.

[23]  C. Masters,et al.  Oligodendrocytes from neural stem cells express &agr;-synuclein: increased numbers from presenilin 1 deficient mice , 2002, Neuroreport.

[24]  J. Trojanowski,et al.  Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .

[25]  A. Dürr,et al.  Genetics of movement disorders , 1996, Current opinion in neurology.

[26]  Bradley T. Hyman,et al.  Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration , 2002, Acta Neuropathologica.

[27]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[28]  P. Lansbury.  Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. Mizukawa,et al.  MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior. , 1987, European neurology.

[30]  M. Jaber,et al.  Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice , 2003, Neuroscience.

[31]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[32]  Hitoshi Takahashi,et al.  NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease , 1997, Neuroscience Letters.

[33]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[34]  J. Trojanowski,et al.  Mouse Model of Multiple System Atrophy α-Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration , 2005, Neuron.

[35]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[36]  Makoto Hashimoto,et al.  Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters , 2002, Journal of neuroscience research.

[37]  Hitoshi Takahashi,et al.  Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy , 1998, Acta Neuropathologica.

[38]  D. Dickson,et al.  Multiple System Atrophy: A Sporadic Synucleinopathy , 1999, Brain pathology.

[39]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Trojanowski,et al.  α‐synuclein is developmentally expressed in cultured rat brain oligodendrocytes , 2000, Journal of neuroscience research.

[41]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[42]  A. Brice,et al.  Alpha-synuclein and Parkinson's disease , 2000, Cellular and Molecular Life Sciences CMLS.

[43]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[44]  L. Mucke,et al.  Levels and Alternative Splicing of Amyloid β Protein Precursor (APP) Transcripts in Brains of APP Transgenic Mice and Humans with Alzheimer's Disease (*) , 1995, The Journal of Biological Chemistry.

[45]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.

[46]  N. Ogawa,et al.  A simple quantitative bradykinesia test in MPTP-treated mice. , 1985, Research communications in chemical pathology and pharmacology.

[47]  D. Dickson,et al.  Alpha-synuclein and the Lewy body disorders. , 2001, Current opinion in neurology.

[48]  Makoto Hashimoto,et al.  Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease , 1998, Brain Research.

[49]  E. Masliah,et al.  Alpha-synuclein overexpression in oligodendrocytic cells results in impaired adhesion to fibronectin and cell death , 2005, Molecular and Cellular Neuroscience.

[50]  H. Ischiropoulos,et al.  Oxidative stress and nitration in neurodegeneration: cause, effect, or association? , 2003, The Journal of clinical investigation.

[51]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[52]  Pico Caroni,et al.  Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.

[53]  M. Mallory,et al.  Early formation of mature amyloid‐β protein deposits in a mutant APP transgenic model depends on levels of Aβ1–42 , 2001, Journal of neuroscience research.

[54]  E. Masliah,et al.  Alpha‐synuclein in Lewy Body Disease and Alzheimer's Disease , 1999, Brain pathology.

[55]  M. Ikeda,et al.  Constant involvement of the Betz cells and pyramidal tract in multiple system atrophy: a clinicopathological study of seven autopsy cases , 2000, Acta Neuropathologica.

[56]  P. Lantos,et al.  The definition of multiple system atrophy: a review of recent developments. , 1998, Journal of neuropathology and experimental neurology.

[57]  Joseph P Huston,et al.  Behavioral phenotyping of the MPTP mouse model of Parkinson's disease , 2001, Behavioural Brain Research.

[58]  C. Marsden,et al.  Cognitive performance in multiple system atrophy. , 1992, Brain : a journal of neurology.

[59]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[60]  Hideo Fujiwara,et al.  Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes , 2002 .

[61]  K. Jellinger,et al.  The role of α-synuclein in the pathogenesis of multiple system atrophy , 2005, Acta Neuropathologica.

[62]  T. Montine,et al.  Immunohistochemical and Biochemical Studies Demonstrate a Distinct Profile of α‐Synuclein Permutations in Multiple System Atrophy , 2000, Journal of neuropathology and experimental neurology.

[63]  V. Uversky,et al.  The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice , 2002, The Journal of Biological Chemistry.

[64]  Michel Goedert,et al.  Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.

[65]  E. Masliah,et al.  Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro , 1999 .

[66]  E. Masliah,et al.  Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP 1 1 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 2004, Experimental Neurology.

[67]  Makoto Hashimoto,et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  T. Sherer,et al.  Animal models of Parkinson's disease. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[69]  Jonathan Salcedo,et al.  Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α-Synuclein , 2004, The Journal of Neuroscience.

[70]  D. Burn,et al.  Multiple system atrophy: cellular and molecular pathology , 2001, Molecular pathology : MP.

[71]  W. Poewe,et al.  Glial cell death induced by overexpression of α‐synuclein , 2001 .

[72]  A. Iwai.  Properties of NACP/α-synuclein and its role in Alzheimer’s disease , 2000 .

[73]  Hitoshi Takahashi,et al.  α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.

[74]  J. Culvenor,et al.  α‐Synuclein Immunoisolation of Glial Inclusions from Multiple System Atrophy Brain Tissue Reveals Multiprotein Components , 1999, Journal of neurochemistry.

[75]  E. Masliah,et al.  Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. , 1996, The American journal of pathology.

[76]  N. Ogawa,et al.  Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion , 1997, Journal of Neuroscience Methods.

[77]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[78]  S. Speciale,et al.  MPTP: insights into parkinsonian neurodegeneration. , 2002, Neurotoxicology and teratology.

[79]  K. Schmid,et al.  Cell Death Mechanisms in Multiple System Atrophy , 1998, Journal of neuropathology and experimental neurology.

[80]  V. Friedrich,et al.  Myelin basic protein gene contains separate enhancers for oligodendrocyte and Schwann cell expression , 1992, The Journal of cell biology.

[81]  E. Masliah,et al.  An antiaggregation gene therapy strategy for Lewy body disease utilizing β-synuclein lentivirus in a transgenic model , 2004, Gene Therapy.